2,6-二氨基己酸乙酯双盐酸盐

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 2,6-二氨基己酸乙酯双盐酸盐
• 英文名称: ethyl 2,6-diaminohexanoate;hydron;dichloride
• 化学式: C8H20Cl2N2O2
• 分子量: 247.16
• InChiKey: DZIYAIZKJOHVQC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.85
• 重原子数：
  14
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  78.3
• 氢给体数：
  4
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-氟-4-硝基苯甲醚 、 2,6-二氨基己酸乙酯双盐酸盐 以6%的产率得到
  参考文献：
  名称：

  PLEIXATS, R.;FIGUEREDO, M.;MARQUET, J.;MORENO-MANAS, M.;CANTOS, A., TETRAHEDRON, 45,(1989) N4, C. 7817-7826

  摘要：

  DOI：

文献信息

• METHOD FOR PRODUCING CARBAMATE AND METHOD FOR PRODUCING ISOCYANATE
  申请人：ASAHI KASEI KABUSHIKI KAISHA

  公开号：US20210179548A1

  公开（公告）日：2021-06-17

  The present invention provides a method for producing a carbamate that includes a step (1) and a step (2) described below: (1) a step of producing a compound (A) having a urea linkage, using an organic primary amine having at least one primary amino group per molecule and at least one compound selected from among carbon dioxide and carbonic acid derivatives, at a temperature lower than the thermal dissociation temperature of the urea linkage; and (2) a step of reacting the compound (A) with a carbonate ester to produce a carbamate.

  本发明提供了一种生产碳酸酯的方法，包括以下步骤：(1)通过使用每个分子至少含有一个一次氨基团的有机初级胺和碳酸气体或碳酸衍生物中选择的至少一种化合物，在低于尿素键热解温度的温度下，生产具有尿素键的化合物(A)；以及(2)将化合物(A)与碳酸酯反应以生产碳酸酯。
• BILE ACID OLIGOMER CONJUGATE FOR NOVEL VESICULAR TRANSPORT AND USE THEREOF
  申请人：MEDIPLEX CORP.

  公开号：US20150290335A1

  公开（公告）日：2015-10-15

  The present invention relates to a method for preparing an end site-specific macromolecule-bile acid oligomer conjugate, comprising conjugating a bile acid oligomer which is prepared by oligomerization of two or more bile acid monomers to the terminal site of a macromolecule; a method for body absorption of an end site-specific macromolecule-bile acid oligomer conjugate, comprising administering the macromolecule-bile acid oligomer conjugate prepared by the above method to a subject orally; an end site-specific macromolecule-bile acid oligomer conjugate wherein the bile acid oligomer is conjugated to the terminal site of macromolecule; a composition comprising the conjugate; an oral formulation for macromolecule comprising the conjugate, a solubilizer, an excipient, a disintegrant, a binder, and a lubricant; a pharmaceutical composition comprising a heparin-bile acid oligomer conjugate wherein the bile acid oligomer is conjugated to the terminal site of heparin; and a method for treating thrombosis using said composition.

  本发明涉及一种制备端点特异性大分子-胆酸寡聚体共轭物的方法，包括将由两个或更多胆酸单体寡聚而成的胆酸寡聚体共轭到大分子的末端位点；一种通过口服将上述方法制备的大分子-胆酸寡聚体共轭物给予受试者的端点特异性大分子-胆酸寡聚体共轭物的体内吸收方法；一种胆酸寡聚体共轭到大分子末端位点的端点特异性大分子-胆酸寡聚体共轭物；一种包括该共轭物的组合物；一种包括该共轭物、溶剂、赋形剂、崩解剂、粘合剂和润滑剂的大分子口服制剂；一种包括胶原酶-胆酸寡聚体共轭物的药物组合物，其中胆酸寡聚体共轭到肝素的末端位点；以及使用该组合物治疗血栓形成的方法。
• Multi-Armed Forms of Activated Polyoxazoline and Methods of Synthesis Thereof
  申请人：Harris J. Milton

  公开号：US20100249368A1

  公开（公告）日：2010-09-30

  The present disclosure provides novel POZ-2 derivatives, methods for synthesizing POZ-2 derivatives and intermediates useful in such methods. In one embodiment, the POZ-2 derivative comprises two linear POZ chains of the present disclosure linked directly or indirectly to a branching moiety that contains a functional group for linking the POZ-2 derivative to the target molecule. Target molecule-POZ-2 conjugates are also described. In certain embodiment, the POZ-2 derivatives have low polydispersity values and a decreased amount of impurities produced by unwanted side reactions, such as, but not limited to, chain transfer.

  本公开提供了新型POZ-2衍生物，以及用于合成POZ-2衍生物和在这些方法中有用的中间体的方法。在一个实施例中，POZ-2衍生物包括两个线性POZ链，这些链直接或间接地连接到一个分支基团，该基团含有用于将POZ-2衍生物连接到目标分子的功能基团。还描述了目标分子-POZ-2共轭物。在某些实施例中，POZ-2衍生物具有低聚分散度值和减少不必要的副反应产生的杂质量，例如但不限于链转移。
• Antitumoral bioconjugates of hyaluronic acid or its derivatives obtained by indirect chemical conjugation
  申请人：FIDIA FARMACEUTICI S.p.A.

  公开号：EP2537533A2

  公开（公告）日：2012-12-26

  The present invention describes a new group of bioconjugates which can be obtained by means of indirect synthesis, via a molecular spacer, between hyaluronic acid and/or its derivatives and drugs with an antitumoral activity belonging to different groups, their preparation process and use in the oncological field. The new derivatives, in relation to the type of bond and Substitution degree, have different physico-chemical properties which improve their tolerability and efficiency and allow a more accurate modulation of the dosage, exploiting an active targeting mechanism.

  本发明描述了一组新的生物共轭物，这组生物共轭物可以通过分子间隔物，在透明质酸和/或其衍生物与属于不同组别的具有抗肿瘤活性的药物之间间接合成，并描述了其制备过程和在肿瘤领域的应用。这些新衍生物在键的类型和取代度方面具有不同的物理化学特性，从而提高了它们的耐受性和效率，并能利用活性靶向机制更准确地调节剂量。
• DEGRADABLE SPIRAL COATED STENT WITH CONTROLLABLE GRADIENT, PREPARATION METHOD THEREFOR AND USE THEREOF
  申请人：Zhuhai Ruizhan Biomaterials Co., Ltd.

  公开号：EP3818995A1

  公开（公告）日：2021-05-12

  Disclosed are a spiral coated stent with controllable gradient degradation, a preparation method thereof and an application thereof. The spiral coated stent with controllable gradient degradation is composed of a degradable medical polyurethane and a degradable magnesium alloy material, wherein the degradable medical polyurethane contains a following chemical structure: PCL-PEG-PCL, wherein a molecular weight of the PEG is 200 to 1,000 and the molecular weight of the PCL is 200 to 10,000, and the degradable magnesium alloy material is of a spiral stent structure; and physical properties of the spiral coated stent with controllable gradient degradation need to satisfy the following technical parameters that: a breaking strength needs to be no less than 1 N, a pressure resistance needs to be no less than 2 N, and a degradation characteristic of the magnesium alloy after surface treatment shows gradient degradation with different time.

  本发明公开了一种可控梯度降解螺旋涂层支架、其制备方法及其应用。可控梯度降解螺旋涂层支架由可降解医用聚氨酯和可降解镁合金材料组成，其中可降解医用聚氨酯包含以下化学结构：PCL-PEG-PCL，其中PEG的分子量为200～1000，PCL的分子量为200～10000，可降解镁合金材料为螺旋支架结构；可控梯度降解螺旋涂层支架的物理性能需满足以下技术参数：断裂强度不小于1N，抗压强度不小于2N，镁合金表面处理后的降解特性随时间变化呈梯度降解。